Genome & Co. · KRX:314130

Genome & Co. financial statements

Genome & Co.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue24.6B27.7B14.3B14.1B451.2M
Cost of revenue11.2B12.1B10.2B8.49B77.0M
Gross profit13.4B15.7B4.06B5.60B374.2M
Research and development11.9B13.4B25.7B36.8B21.3B
Selling, general and administrative16.1B22.0B28.7B19.7B6.96B
Operating income-29.2B-32.6B-57.4B-57.5B-36.1B
Depreciation and amortization6.67B4.47B5.31B4.61B2.59B
EBITDA-22.6B-28.1B-52.1B-52.9B-33.5B
Interest expense4.72B3.54B1.74B175.0M54.9M
Income before tax-8.67B-28.2B-51.9B-58.0B-36.0B
Net income-6.43B-20.1B-47.5B-51.8B-34.1B
Earnings per share, basic-184.22-647.65-1,611.73-1,839.34-1,212.72

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents15.6B65.5B56.4B72.2B36.0B
Short-term investments21.2B11.7B26.1B29.3B41.1B
Receivables1.86B3.74B2.05B2.79B759.2M
Inventory5.98B5.77B3.57B2.24B1.33B
Current assets52.3B91.9B97.0B116.9B81.8B
Property, plant and equipment27.9B34.6B21.5B
Goodwill11.1B14.1B14.1B16.5B16.5B
Total assets145.0B147.3B162.1B173.0B137.2B
Accounts payable509.1M481.2M340.2M205.2M321.4M
Current liabilities22.8B29.8B28.2B11.1B9.83B
Long-term debt9.00B9.64B
Total liabilities30.4B99.0B99.6B75.7B23.8B
Shareholders' equity105.8B48.3B62.4B97.3B92.7B
Shares outstanding34.9M31.1M29.5M28.2M28.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-18.4B-7.61B-31.0B-36.0B-26.2B
Capital spending-497.7M-4.19B-19.0B-7.28B-3.38B
Free cash flow-18.9B-20.5B-51.3B-50.8B-29.5B
Cash from investing11.6B-15.4B-6.38B
Cash from financing5.25B30.6B78.6B
Share buybacks-54.2B33.8M81.5M80.2B
Change in cash-50.0B9.19B-15.9B36.2B-67.9B